(HealthDay News) – Elevated pulse pressure (PP) is linked to cerebrospinal fluid (CSF)-based biomarkers related to Alzheimer’s disease in cognitively normal, older adults, according to a study published online Nov. 13 in Neurology.
To examine the correlation between PP and CSF-based Alzheimer’s disease biomarkers, Daniel A. Nation, PhD, from the Veterans Affairs San Diego Healthcare System, and colleagues conducted blood pressure assessments for determination of PP and lumbar puncture for measurement of CSF β-amyloid 1 to 42 (Aβ1-42) and phosphorylated tau (P-tau) in 177 cognitively normal, stroke-free older adult participants (aged 55 to 100 years). PP was calculated as systolic − diastolic blood pressure.
The researchers observed significant correlations for elevated PP with increased P-tau, reduced Aβ1-42, and increased P-tau to Aβ1-42 ratio. After adjustment for covariates, the significant correlation persisted for PP with P-tau and P-tau to Aβ1-42 ratio, but not for PP with Aβ1-42. Significant associations were seen for increased PP with all biomarkers in younger participants (aged 55–70 years), but not in older participants (aged 70–100 years), in multivariate analyses.
“PP elevation is associated with increased CSF P-tau and decreased Aβ1-42 in cognitively normal older adults, suggesting that pulsatile hemodynamics may be related to amyloidosis and tau-related neurodegeneration,” the authors conclude. “The relationship between PP and CSF biomarkers is age-dependent and observed only in participants in the fifth and sixth decades of life.”
Several authors disclosed financial ties to the pharmaceutical industry.